Barcelona-based Werfen announced on November 3 its acquisition of Immucor, Inc., a Norcross, Georgia-based provider of transfusion and transplantation diagnostic products worldwide, from San Francisco-based private equity firm TPG Capital. This acquisition will allow Werfen to expand its portfolio of specialized diagnostics solutions for hospitals and clinical laboratories.
According to the LevinPro HC database, this marks the 114th acquisition in the Laboratories, MRI and Dialysis sector this year, and the 63rd deal in the diagnosis subsector.
The purchase price is expected to be approximately $2 billion, with closing subject to customary regulatory approvals. The acquisition is being funded with a mix of cash on hand and new senior credit facilities.
Werfen was advised by Barclays Capital and Milbank LLP. The sellers and Immucor were advised by
Evercore Group LLC and Ropes & Gray LLP. BBVA, BNP Paribas, CaixaBank and HSBC Holding plc provided commitments for the new senior credit facilities.
Werfen is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells and data management solutions for use primarily in hospitals and independent clinical laboratories. Werfen operates directly in nearly 30 countries and in more than 100 territories through distributors.
